Shares of Arvinas (ARVN) are up about 3% in pre-market trading at $18.40. Last night, in a 13G filing, Citadel Securities disclosed a 5.1% ...

Results from clinical trials that wrap up soon could soon push shares of Recursion Pharmaceuticals (NASDAQ: RXRX), and Arvinas (NASDAQ: ARVN) through the roof. Before you get excited and fill your ...

Check the time stamp on this data. Updated AI-Generated Signals for Arvinas Inc. (ARVN) available here: ARVN. Type a few ...

In this article, we are going to take a look at where Arvinas, Inc. (NASDAQ:ARVN) stands against the other small-cap ...

In this article, we are going to take a look at where Arvinas, Inc. (NASDAQ:ARVN) stands against the other small-cap biotech stocks. The biotechnology sector is expanding quickly due to rising ...

Below is a chart showing JBLU's trailing twelve month trading history, with the $6 strike highlighted in orange: And Arvinas Inc (Symbol: ARVN) saw options trading volume of 6,206 contracts ...

Analysts have been eager to weigh in on the Healthcare sector with new ratings on Arvinas Holding Company (ARVN – Research Report) and ...

In trading on Thursday, shares of Arvinas Inc (Symbol: ARVN) entered into oversold territory, hitting an RSI reading of 28.8, after changing hands as low as $17.85 per share. By comparison ...

Shares of Arvinas, Inc. (NASDAQ:ARVN – Get Free Report) have been assigned a consensus recommendation of “Moderate Buy” from ...

Arvinas-Pfizer Partner Cancer Drug Trial Shows 63% Clinical Benefit In Breast Cancer Patients Arvinas and Pfizer share Phase 1b TACTIVE-U trial results showing 62.5% clinical benefit rate and ...

Nov. 27, 2024 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today announced that ...